

Product Name: Abiraterone acetate Revision Date: 01/10/2020

Product Data Sheet

Abiraterone acetate

Cat. No.: A8202

CAS No.: 154229-18-2 **Formula:** C26H33NO2


M.Wt: 391.55

Synonyms:

Target: Metabolism

Pathway: P450

Storage: Store at -20°C



Solvent & Solubility

 \geqslant 15.7mg/mL in Ethanol, \geqslant 11.22 mg/mL in DMSO with ultrasonic and warming,insoluble in H2O

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.5540 mL	12.7698 mL	25.5395 mL
	5 mM	0.5108 mL	2.5540 mL	5.1079 mL
	10 mM	0.2554 mL	1.2770 mL	2.5540 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Shortsummary	Cytochrome p450 17a1 inhibitor			
IC ₅₀ & Target	72 nM (CYP17)			
In Vitro	Cell Viability Assay			
	Cell Line:	PC-3 cells		
	Preparation method:	The solubility of this compound in DMSO is limited. General tips for obtaining a		
		higher concentration: Please warm the tube at 37 °C for 10 minutes and/or		
		shake it in the ultrasonic bath for a while. Stock solution can be stored below -		
		20 °C for several months.		
	Reacting conditions:	0.1 ~ 25 μM; 16 hrs		
	Applications:	In PC-3 cells co-transfected with ARE3-luciferase and wild type or mutant		

		androgen receptor (AR), Abiraterone Acetate at the dose up to 25 µM did not any obvious increase in luciferase activity. However, Abiraterone Acetate dose-dependently inhibited stimulated wild type and mutant AR activity, with	
		significant inhibition observed at the doses ≤ 10 μM.	
	Animal experiment		
In Vivo	Animal models:	Male NOD/SCID mice bearing LAPC4 cells	
	Dosage form:	0.5 mmol/kg/d; i.p.; 5 days per week, for 4 weeks	
	Applications:	Abiraterone Acetate at the dose of 0.5 mmol/kg/d resulted in serum	
		concentrations ranging from 0.5 to 1 mmol/L. Compared with the control group,	
		Abiraterone Acetate treatment significantly inhibited "castration-resistant"	
		prostate cancer progression in the robustly growing subset, effectively	
		inhibiting tumor growth over 4 weeks of treatment.	
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may	
		slightly differ with the theoretical value. This is caused by an experimental	
		system error and it is normal.	

Product Citations

See more customer validations on www.apexbt.com.

References

- [1]. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res. 2012 May 1;72(9):2176-82.
- [2]. Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer. Clin Cancer Res. 2012 Jul 1;18(13):3571-9.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054. Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

